Developer docs
API playgroundTry for free, no card

Search company profiles

ERS Genomics

Full company profile

uuid000bv7e

Namestring
ERS Genomics
Legal namestring
ERS Genomics Limited
Websiteurl
ersgenomics.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ERS Genomics Limited is a Dublin-based, privately held intellectual property licensing company founded in 2014 to commercialize the foundational CRISPR/Cas9 patent estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier and her collaborators across Carnegie Institution, UC Berkeley, and the University of Vienna (the CVC portfolio). The company holds rights to 100+ granted patents spanning the United States, Europe, Japan, and China, covering compositions and methods for guiding Cas9 to target DNA in all cell types, including mammalian, bacterial, plant, and fungal systems, as well as Cas9 variants supporting CRISPRi, CRISPRa, and base editing applications. ERS exclusively licenses all fields outside of direct human gene and cell therapies, with an exclusive sublicense arrangement with Corteva Agriscience covering all agricultural crops.

The company monetizes the CVC estate through a three-tier non-exclusive licensing structure: a Standard License for established organizations covering internal research, commercial products, services, and an optional bioproduction add-on; an Express License for small teams under 15 employees and under $10M in funding, priced at $15,000 signature fee and $15,000 annual maintenance over a five-year term; and an Early Access Express License launched in February 2026 for pre-seed innovators under $1M in funding. Distribution combines a dedicated licensing team, an online self-serve portal, and regional business development consultants in North America, the UK, and India.

ERS serves more than 160 licensees globally across BioPharma, Life Science Tools, Animal Health, Plants, and Synthetic Biology, with named enterprise customers including GSK, Merck, Bayer, Thermo Fisher Scientific, Danaher, PerkinElmer, Charles River Laboratories, Corteva Agriscience, and Cargill. The company is governed by a Board chaired by co-founder Shaun Foy, with co-founders Prof. Charpentier and Dr. Rodger Novak, and is led day-to-day by CEO John E. Milad, supported by a lean executive team including a VP of Finance, General Counsel, Head of Commercial Operations, and regional BD leadership.

Short descriptiontext

ERS Genomics is a Dublin-based intellectual property licensing company that grants non-exclusive access to the foundational CVC CRISPR/Cas9 patent portfolio to pharmaceutical, life sciences, agricultural, and synthetic biology organizations worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR Cas9 licensing, gene editing patents, biotechnology IP licensing, genome editing IP, CRISPR patent portfolio
Industry1 code
PRIMARYBPAHAMAA
Patent Prosecution & Portfolio Management
NAICS code3 codes
  • Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)533
  • Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)533110
  • Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)53311
SIC code1 code
  • Patent Owners & Lessors6794
Product category
Biotechnology Intellectual Property Licensing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CRISPR/Cas9 IP Licensing
TypeLicensing Royalties
Description

ERS Genomics generates revenue through licensing its foundational CRISPR/Cas9 patent portfolio. The company offers multiple license tiers including Standard License for established organizations, Express License for small teams (under 15 employees, under $10M funding), and Early Access Express License for pre-seed startups. Revenue comes from one-time signature fees and ongoing annual maintenance fees.

ersgenomics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details3 tiers
1Standard License for established organizations
ModelSubscriptionBilling cadenceAnnual
Notes

Comprehensive licensing for established organizations requiring internal research use rights and commercial product or service offerings. Includes internal research use rights, commercial product offerings, service offerings, and optional bioproduction add-on. Dedicated licensing support provided.

ersgenomics.com
2Express License for small teams
ModelSubscriptionBilling cadenceAnnual
Notes

Non-exclusive worldwide license for internal research use of CRISPR/Cas9. Eligibility: Under 15 employees, Under USD 10M in funding, Company less than 5 years old. Fees: One-time signature fee: $15,000 USD, Annual maintenance fee: $15,000 USD. Term: 5-year licence term. Standard field of use - cannot commercialize CRISPR in any way, nor assign rights to subcontractors.

ersgenomics.com
3Early Access Express License for pre-seed startups
ModelSubscriptionBilling cadenceAnnual
Notes

Reduced-cost entry point for unfunded early startups. Pre-seed stage, less than $1M in funding to date. Significantly reduced upfront fee and annual maintenance fee. Max 3-year term at reduced rate. Automatically converts to full Express Licence terms after Early Access Period.

ersgenomics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ERS Genomics licenses the foundational CVC CRISPR/Cas9 intellectual property portfolio — derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier — to organizations worldwide for use across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology. The company offers tiered non-exclusive licenses (Standard, Express, and Early Access Express) that grant freedom to operate for CRISPR/Cas9 research and commercial applications outside direct human therapeutics. Revenue is generated through one-time signature fees and recurring annual maintenance fees.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 160+ organizations worldwide have secured their Freedom to Operate with foundational CRISPR/Cas9 IP from ERS Genomics
+2 more records
Product overview1 text field

ERS Genomics operates as a CRISPR/Cas9 intellectual property licensing company offering access to the CVC Patent Portfolio — the foundational CRISPR/Cas9 patent estate derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier. The company offers a tiered licensing structure: the Standard License for established organizations covering internal research, commercial products, services, and optional bioproduction; the Express License for small startups under 15 employees and under $10M in funding at $15,000/year for internal research use; and the Early Access Express License — a reduced-cost entry point for pre-seed innovators under $1M in funding for up to three years. All licenses are non-exclusive and cover CRISPR/Cas9 applications across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology fields worldwide.

Product and service4 records
1CVC Patent Portfolio (Foundational CRISPR/Cas9 IP)
CategoryBiotechnology IP Licensing
Description

The foundational CRISPR/Cas9 intellectual property estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier, covering core gene-editing methods and compositions across all cell types including mammalian, bacterial, plant, and fungal systems. Provides freedom to operate for organizations using CRISPR/Cas9 in research and commercial applications outside direct human therapeutics.

2Standard License
CategoryBiotechnology IP Licensing
Description

Comprehensive licensing for established organizations requiring internal research use rights and commercial product or service offerings, with optional bioproduction add-on. Includes dedicated licensing support from the ERS licensing team.

3Express License
CategoryBiotechnology IP Licensing
Description

Non-exclusive worldwide license for internal research use of CRISPR/Cas9 for small organizations. Available to companies under 15 employees, under USD 10M in funding, and less than 5 years old. One-time signature fee of $15,000 USD, annual maintenance fee of $15,000 USD, 5-year term.

4Early Access Express License
CategoryBiotechnology IP Licensing
Description

Reduced-cost entry point for pre-seed, pre-revenue stage innovators, providing a subset of Express License rights. Designed for companies with less than $1M in funding. Offers substantially reduced upfront and annual fees for up to three years, automatically converting to full Express License terms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Aurigene Pharmaceutical Services Limited
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-05-13
Description

ERS Genomics signed a non-exclusive license agreement with Aurigene Pharmaceutical Services Limited, granting access to its foundational CRISPR/Cas9 patent portfolio. The agreement enables Aurigene to integrate precision genome editing capabilities into its drug discovery platforms, supporting global pharmaceutical and biotechnology partners across small molecule and biologics programs. Aurigene is a subsidiary of Dr. Reddy's Laboratories and operates as an end-to-end integrated CRDMO.

ersgenomics.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-10
Description

Non-exclusive license agreement enabling Dyadic to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. The license supports both Dyadic's internal product pipeline and the customized production strains developed for partners across life sciences, food and nutrition, and bio-industrial sectors.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-27
Description

Non-exclusive CRISPR/Cas9 license agreement providing Jumpcode access to ERS' patent portfolio to enhance next-generation sequencing capabilities. The partnership empowers Jumpcode to advance sensitivity and efficiency of NGS and expand applications across multiple research and clinical areas including basic research, infectious disease detection, molecular diagnostics, and oncology.

4Corteva Agriscience
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-13
Description

Exclusive sublicense arrangement for plant agriculture. Corteva (previously DowDuPont and Pioneer) holds exclusive rights for commercial and sub-licensing rights for CRISPR/Cas9 use in all agricultural crops. Corteva is the world's leading developer and supplier of advanced plant genetics, providing seeds to farmers in more than 90 countries.

ersgenomics.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-04-09
Description

Licensee case study partner using CRISPR/Cas9 for advanced disease modelling, assay development, and drug discovery services. Bioneer operates a 3,350-square-meter facility in Hørsholm, Denmark, and uses CRISPR for creating genetically modified cell lines, reporter cell lines, and inducible gene expression systems for neurological disease research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage in-vivo CRISPR/Cas9 developer (using Charpentier/Doudna foundational IP). Comparable as a deep CRISPR therapeutics developer that depends on the type of foundational IP ERS licenses, and representative of the cell and gene therapy market ERS is structurally excluded from.

TypeEmerging player
Description

CRISPR-based diagnostics and gene editing company co-founded by Jennifer Doudna. Comparable as a CRISPR platform player addressing the same set of life sciences, agricultural, and industrial customers that ERS licenses, and representative of the broader Doudna/Charpentier IP ecosystem.

TypeBroad incumbent
Description

CRISPR-based gene editing company originally licensed under the Broad Institute portfolio. It provides a useful comparable for how foundational CRISPR IP translates into a therapeutic pipeline and the licensing economics that support it.

TypeEmerging player
Description

Pioneer of base editing — a direct application covered by ERS's CVC IP for nCas9/base editing variants. Beam is a relevant comparable for the next-generation editing applications that ERS's Cas9 variant patents (nCas9, dCas9) enable.

TypeDirect peer
Description

Holds foundational competing CRISPR/Cas9 patent claims (Zhang lab) and is the principal IP adversary in the CVC interference. Both Broad and ERS license Cas9 IP to the global research and commercial market, with overlapping customer rosters across pharma, life sciences, and agriculture.

TypeDirect peer
Description

Korean biotechnology company that holds independent foundational CRISPR/Cas9 IP and licenses it to global research and commercial users. It is one of the few direct IP-level peers to ERS in the CRISPR licensing market.

TypeEmerging player
Description

Provider of CRISPR tools, reagents, and cell engineering services to researchers and commercial customers — directly comparable as an ERS licensee segment (Life Science Tools) and a key customer type for ERS's Express and Standard licensing programs.

TypeEmerging player
Description

CRISPR genome editing company (originally spun out of Doudna lab) developing both therapeutic and non-therapeutic applications. Comparable as a CRISPR platform company that both uses and depends on foundational IP similar to ERS's CVC portfolio.

TypeBroad incumbent
Description

Clinical-stage gene editing company co-founded by Emmanuelle Charpentier that developed CASGEVY (the first FDA-approved CRISPR therapy) in partnership with Vertex. While it operates in the therapeutic field ERS is excluded from, it is a foundational CRISPR company and an important reference point for the value of CVC IP.

TypeOthers
Description

Independent licensing administrator that aggregates and licenses patent pools across technology categories. Comparable as a structural peer in the IP licensing business model, particularly relevant to understanding how a single-purpose patent licensing entity with 100+ granted patents and 100+ licensees is valued and operated.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ERS Genomics

Biotechnology Intellectual Property Licensingersgenomics.com

ERS Genomics is a Dublin-based intellectual property licensing company that grants non-exclusive access to the foundational CVC CRISPR/Cas9 patent portfolio to pharmaceutical, life sciences, agricultural, and synthetic biology organizations worldwide.

What ERS Genomics does

ERS Genomics Limited is a Dublin-based, privately held intellectual property licensing company founded in 2014 to commercialize the foundational CRISPR/Cas9 patent estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier and her collaborators across Carnegie Institution, UC Berkeley, and the University of Vienna (the CVC portfolio). The company holds rights to 100+ granted patents spanning the United States, Europe, Japan, and China, covering compositions and methods for guiding Cas9 to target DNA in all cell types, including mammalian, bacterial, plant, and fungal systems, as well as Cas9 variants supporting CRISPRi, CRISPRa, and base editing applications. ERS exclusively licenses all fields outside of direct human gene and cell therapies, with an exclusive sublicense arrangement with Corteva Agriscience covering all agricultural crops.

The company monetizes the CVC estate through a three-tier non-exclusive licensing structure: a Standard License for established organizations covering internal research, commercial products, services, and an optional bioproduction add-on; an Express License for small teams under 15 employees and under $10M in funding, priced at $15,000 signature fee and $15,000 annual maintenance over a five-year term; and an Early Access Express License launched in February 2026 for pre-seed innovators under $1M in funding. Distribution combines a dedicated licensing team, an online self-serve portal, and regional business development consultants in North America, the UK, and India.

ERS serves more than 160 licensees globally across BioPharma, Life Science Tools, Animal Health, Plants, and Synthetic Biology, with named enterprise customers including GSK, Merck, Bayer, Thermo Fisher Scientific, Danaher, PerkinElmer, Charles River Laboratories, Corteva Agriscience, and Cargill. The company is governed by a Board chaired by co-founder Shaun Foy, with co-founders Prof. Charpentier and Dr. Rodger Novak, and is led day-to-day by CEO John E. Milad, supported by a lean executive team including a VP of Finance, General Counsel, Head of Commercial Operations, and regional BD leadership.

ERS Genomics firmographics

Firmographics
Name
ERS Genomics
Legal name
ERS Genomics Limited
Website
https://ersgenomics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
ERS Genomics is a Dublin-based intellectual property licensing company that grants non-exclusive access to the foundational CVC CRISPR/Cas9 patent portfolio to pharmaceutical, life sciences, agricultural, and synthetic biology organizations worldwide.
Ownership category
akta.pro rank

ERS Genomics industry classification

Industry
Product category
Biotechnology Intellectual Property Licensing
NAICS
Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533110), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (53311)
SIC
Patent Owners & Lessors (6794)
akta.pro industry
PRIMARYBPAHAMAA
Patent Prosecution & Portfolio Management

Keywords

  • CRISPR Cas9 licensing
  • Gene editing patents
  • Biotechnology IP licensing
  • Genome editing IP
  • CRISPR patent portfolio

Where ERS Genomics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ERS Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. CRISPR/Cas9 IP Licensing: ERS Genomics generates revenue through licensing its foundational CRISPR/Cas9 patent portfolio. The company offers multiple license tiers including Standard License for established organizations, Express License for small teams (under 15 employees, under $10M funding), and Early Access Express License for pre-seed startups. Revenue comes from one-time signature fees and ongoing annual maintenance fees.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualStandard License for established organizations
SubscriptionAnnualExpress License for small teams
SubscriptionAnnualEarly Access Express License for pre-seed startups

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

ERS Genomics product offering

Product offering

Core offering

ERS Genomics licenses the foundational CVC CRISPR/Cas9 intellectual property portfolio — derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier — to organizations worldwide for use across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology. The company offers tiered non-exclusive licenses (Standard, Express, and Early Access Express) that grant freedom to operate for CRISPR/Cas9 research and commercial applications outside direct human therapeutics. Revenue is generated through one-time signature fees and recurring annual maintenance fees.

Product overview

ERS Genomics operates as a CRISPR/Cas9 intellectual property licensing company offering access to the CVC Patent Portfolio — the foundational CRISPR/Cas9 patent estate derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier. The company offers a tiered licensing structure: the Standard License for established organizations covering internal research, commercial products, services, and optional bioproduction; the Express License for small startups under 15 employees and under $10M in funding at $15,000/year for internal research use; and the Early Access Express License — a reduced-cost entry point for pre-seed innovators under $1M in funding for up to three years. All licenses are non-exclusive and cover CRISPR/Cas9 applications across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology fields worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • CVC Patent Portfolio (Foundational CRISPR/Cas9 IP) The foundational CRISPR/Cas9 intellectual property estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier, covering core gene-editing methods and compositions across all cell types including mammalian, bacterial, plant, and fungal systems. Provides freedom to operate for organizations using CRISPR/Cas9 in research and commercial applications outside direct human therapeutics.
  • Standard License Comprehensive licensing for established organizations requiring internal research use rights and commercial product or service offerings, with optional bioproduction add-on. Includes dedicated licensing support from the ERS licensing team.
  • Express License Non-exclusive worldwide license for internal research use of CRISPR/Cas9 for small organizations. Available to companies under 15 employees, under USD 10M in funding, and less than 5 years old. One-time signature fee of $15,000 USD, annual maintenance fee of $15,000 USD, 5-year term.
  • Early Access Express License Reduced-cost entry point for pre-seed, pre-revenue stage innovators, providing a subset of Express License rights. Designed for companies with less than $1M in funding. Offers substantially reduced upfront and annual fees for up to three years, automatically converting to full Express License terms.

Quantifiable outcome

  • 160+ organizations worldwide have secured their Freedom to Operate with foundational CRISPR/Cas9 IP from ERS Genomics
  • +2 more outcomes

Companies that use ERS Genomics

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles5 records

ERS Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

ERS Genomics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • Aurigene Pharmaceutical Services LimitedcoreOEM/ Whitelabel/ Licensing Partner · 13 May 2026ERS Genomics signed a non-exclusive license agreement with Aurigene Pharmaceutical Services Limited, granting access to its foundational CRISPR/Cas9 patent portfolio. The agreement enables Aurigene to integrate precision genome editing capabilities into its drug discovery platforms, supporting global pharmaceutical and biotechnology partners across small molecule and biologics programs. Aurigene is a subsidiary of Dr. Reddy's Laboratories and operates as an end-to-end integrated CRDMO.
  • Dyadic Applied BioSolutionscoreOEM/ Whitelabel/ Licensing Partner · 10 November 2025Non-exclusive license agreement enabling Dyadic to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. The license supports both Dyadic's internal product pipeline and the customized production strains developed for partners across life sciences, food and nutrition, and bio-industrial sectors.
  • Jumpcode GenomicscoreOEM/ Whitelabel/ Licensing Partner · 27 March 2025Non-exclusive CRISPR/Cas9 license agreement providing Jumpcode access to ERS' patent portfolio to enhance next-generation sequencing capabilities. The partnership empowers Jumpcode to advance sensitivity and efficiency of NGS and expand applications across multiple research and clinical areas including basic research, infectious disease detection, molecular diagnostics, and oncology.
  • Corteva AgriscienceflagshipOEM/ Whitelabel/ Licensing Partner · 13 January 2025Exclusive sublicense arrangement for plant agriculture. Corteva (previously DowDuPont and Pioneer) holds exclusive rights for commercial and sub-licensing rights for CRISPR/Cas9 use in all agricultural crops. Corteva is the world's leading developer and supplier of advanced plant genetics, providing seeds to farmers in more than 90 countries.
  • Bioneer A/ScoreOEM/ Whitelabel/ Licensing Partner · 9 April 2024Licensee case study partner using CRISPR/Cas9 for advanced disease modelling, assay development, and drug discovery services. Bioneer operates a 3,350-square-meter facility in Hørsholm, Denmark, and uses CRISPR for creating genetically modified cell lines, reporter cell lines, and inducible gene expression systems for neurological disease research.

Scale indicators4 records

Recent moves6 records

Expansion highlights8 records

ERS Genomics competitors and assessment

Company assessment

Broad incumbents

  • Intellia Therapeutics: Clinical-stage in-vivo CRISPR/Cas9 developer (using Charpentier/Doudna foundational IP). Comparable as a deep CRISPR therapeutics developer that depends on the type of foundational IP ERS licenses, and representative of the cell and gene therapy market ERS is structurally excluded from.
  • Editas Medicine: CRISPR-based gene editing company originally licensed under the Broad Institute portfolio. It provides a useful comparable for how foundational CRISPR IP translates into a therapeutic pipeline and the licensing economics that support it.
  • CRISPR Therapeutics: Clinical-stage gene editing company co-founded by Emmanuelle Charpentier that developed CASGEVY (the first FDA-approved CRISPR therapy) in partnership with Vertex. While it operates in the therapeutic field ERS is excluded from, it is a foundational CRISPR company and an important reference point for the value of CVC IP.

Emerging players

  • Mammoth Biosciences: CRISPR-based diagnostics and gene editing company co-founded by Jennifer Doudna. Comparable as a CRISPR platform player addressing the same set of life sciences, agricultural, and industrial customers that ERS licenses, and representative of the broader Doudna/Charpentier IP ecosystem.
  • Beam Therapeutics: Pioneer of base editing — a direct application covered by ERS's CVC IP for nCas9/base editing variants. Beam is a relevant comparable for the next-generation editing applications that ERS's Cas9 variant patents (nCas9, dCas9) enable.
  • Synthego: Provider of CRISPR tools, reagents, and cell engineering services to researchers and commercial customers — directly comparable as an ERS licensee segment (Life Science Tools) and a key customer type for ERS's Express and Standard licensing programs.
  • Caribou Biosciences: CRISPR genome editing company (originally spun out of Doudna lab) developing both therapeutic and non-therapeutic applications. Comparable as a CRISPR platform company that both uses and depends on foundational IP similar to ERS's CVC portfolio.

Direct peers

  • Broad Institute: Holds foundational competing CRISPR/Cas9 patent claims (Zhang lab) and is the principal IP adversary in the CVC interference. Both Broad and ERS license Cas9 IP to the global research and commercial market, with overlapping customer rosters across pharma, life sciences, and agriculture.
  • ToolGen: Korean biotechnology company that holds independent foundational CRISPR/Cas9 IP and licenses it to global research and commercial users. It is one of the few direct IP-level peers to ERS in the CRISPR licensing market.

Others

  • MPEG LA: Independent licensing administrator that aggregates and licenses patent pools across technology categories. Comparable as a structural peer in the IP licensing business model, particularly relevant to understanding how a single-purpose patent licensing entity with 100+ granted patents and 100+ licensees is valued and operated.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ERS Genomics social profiles

Digital presence

ERS Genomics compliance and trust

Trust signal

Compliance1 record

ERS Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ERS Genomics leadership team

Management profile

Number of profiles

Profiles11 records

ERS Genomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ERS Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ERS Genomics

What does ERS Genomics do?

ERS Genomics licenses the foundational CVC CRISPR/Cas9 intellectual property portfolio — derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier — to organizations worldwide for use across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology. The company offers tiered non-exclusive licenses (Standard, Express, and Early Access Express) that grant freedom to operate for CRISPR/Cas9 research and commercial applications outside direct human therapeutics. Revenue is generated through one-time signature fees and recurring annual maintenance fees.

Is ERS Genomics a public or private company?

ERS Genomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ERS Genomics founded?

ERS Genomics was founded in 2014. It employs 1 to 10 people.

Where is ERS Genomics based?

ERS Genomics is headquartered in San Francisco, United States, in the North America region.

How does ERS Genomics make money?

One revenue line is on record: CRISPR/Cas9 IP Licensing.

Who are ERS Genomics's main competitors?

Broad incumbents on record are Intellia Therapeutics, Editas Medicine and CRISPR Therapeutics. Emerging players are Mammoth Biosciences, Beam Therapeutics, Synthego and Caribou Biosciences. Direct peers are Broad Institute and ToolGen. MPEG LA is listed as an others.

Does ERS Genomics have an API?

No public API is recorded for ERS Genomics.

What industry is ERS Genomics in?

ERS Genomics's product category is Biotechnology Intellectual Property Licensing. Its primary akta.pro industry code is BPAHAMAA, Patent Prosecution & Portfolio Management. Its NAICS code is 533 and its SIC code is 6794.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireERS Genomics and KU Leuven Sign CRISPR/Cas9 License Agreement to Expand CRISPR-Enabled Research ServicesERS Genomics signed a non-exclusive license agreement with KU Leuven's Leuven Viral Vector Core, granting worldwide access to its CRISPR/Cas9 patent portfolio. The agreement enables the LVVC to offer CRISPR-mediated genome editing services, including customized cellular disease models and iPSC lines, for academic and industry researchers.YahooERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and DevelopmentERS Genomics signed a non-exclusive license agreement with Sai Life Sciences, granting access to its CRISPR/Cas9 patent portfolio for research and product development. The deal enables Sai Life Sciences to integrate precision genome editing into its discovery and development platforms, supporting global pharmaceutical and biotechnology partners.PR NewswireERS Genomics and Aurigene Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug DiscoveryERS Genomics Limited signed a non-exclusive license agreement with Aurigene Pharmaceutical Services Limited, granting access to its foundational CRISPR/Cas9 patent portfolio. The agreement enables Aurigene to integrate precision genome editing capabilities into its drug discovery platforms, supporting global pharmaceutical and biotechnology partners across small molecule and biologics programs. The deal adds Aurigene, a subsidiary of Dr. Reddy's Laboratories, to ERS Genomics' growing network of CRISPR licensees.PR NewswireERS Genomics launches new Early Access Express LicenseERS Genomics Limited, a CRISPR intellectual property licensing company, announced the launch of its Early Access Express License, a new streamlined licensing option offering affordable access to its foundational CRISPR/Cas9 patent portfolio for pre-seed and pre-revenue stage innovators. The license grants non-exclusive rights for internal research and development only, with a substantially reduced annual fee for up to three years, automatically transitioning to standard commercial terms as the licensee scales through revenue or funding. This offering complements ERS Genomics' existing licensing programs that provide global access to the CVC CRISPR/Cas9 patent portfolio across applications outside direct human therapeutics.PR NewswireERS Genomics launches new Early Access Express LicenseERS Genomics announced the launch of the Early Access Express License, a new CRISPR/Cas9 intellectual property licensing option targeting pre-seed and pre-revenue stage innovators seeking affordable access to the foundational gene-editing patent portfolio. The license grants non-exclusive rights for internal R&D at a substantially reduced annual fee for up to three years, automatically transitioning to standard commercial licensing as companies scale through revenue or seed financing. The offering extends ERS Genomics' mission to democratize access to CRISPR/Cas9 technology by removing barriers for early-stage companies, academic spinouts, and incubator teams.Investing.comEarnings call transcript: Dyadic’s Q3 2025 results miss forecasts, stock dips By Investing.comDyadic International Inc. reported Q3 2025 earnings with a net loss of $0.06 per share, missing analysts' expectations of a $0.05 loss, while revenue of $1.165 million fell 22.67% short of the $1.5 million forecast and declined from $1.968 million in the same quarter last year. Following the earnings release on November 12, 2025, Dyadic's stock dropped 7.42% in after-hours trading to $0.905. Despite the financial misses, the company announced its first commercial bulk sale of a protein product, a new CRISPR license agreement with ERS Genomics, and an Asia-Pacific partnership with Interlink for market expansion into Japan and South Korea.GlobeNewswireDyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic ProgressDyadic International, Inc. (d/b/a Dyadic Applied BioSolutions) reported Q3 2025 financial results on November 12, 2025, with total revenue declining to $1.165 million from $1.958 million in the same period a year ago, while net loss widened to $1.976 million from $203,000 year-over-year. The company completed a strategic pivot from R&D to commercial focus, rebranded as Dyadic Applied BioSolutions, secured a non-exclusive CRISPR/Cas9 license from ERS Genomics, and received first purchase orders in cell culture media and molecular biology reagents. Cash position strengthened to $10.4 million following a $4.9 million equity offering completed in August 2025, with grant funding from the Gates Foundation and CEPI totaling approximately $2.4 million received during the quarter.GlobeNewswireDyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS GenomicsERS Genomics and Dyadic Applied BioSolutions announced a commercial license agreement granting Dyadic access to ERS' CRISPR/Cas9 patent portfolio. This partnership aims to enhance Dyadic's genetic engineering capabilities, specifically accelerating strain engineering and pathway optimization for its proprietary bioproduction platforms. Financial details of the agreement were not disclosed.GlobeNewswireERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9ERS Genomics launched an Express License platform giving startups under 15 employees and $10 million in funding affordable access to its CRISPR/Cas9 patent portfolio. The non-exclusive internal research license covers over 130 patents worldwide, including over 50 in the US. The platform aims to democratize access to the technology for small research enterprises.